Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fat-burning claim fails

This article was originally published in The Tan Sheet

Executive Summary

Claims that Zylotrim weight-loss supplements more than doubles fat-burning enzyme activity are not supported and should be modified or discontinued, the Electronic Retailing Self-Regulation Program says. The Carlsbad, Calif.-based firm by the same name said it will modify that claim, and a second claim that 80 percent of each pound users lose is "pure body fat." In its March 23 decision, ERSP also determined the firm supported its claim that product users lost 200 percent more weight in combination with diet and exercise compared to subjects who dieted and exercised but did not use the product in two controlled clinical studies on the active ingredient, 3-acetyl-7-oxo-dehydroepiandrosterone. Zylotrim also provided a reasonable basis for the claim that the product is "clinically proven to help reduce body fat and weight.

You may also be interested in...

ERSP trims MytoSlim fat burn claims

Weight Management Institute discontinues marketing claims that its weight-loss supplement can "increase fat burning enzyme activity up to 10 times normal levels" and help users "lose up to 3 times more body fat" amid an Electronic Retailing Self-Regulation Program inquiry. Brea, Calif.-based WMI substantiated the claim that MytoSlim enables "200% more weight loss than diet and exercise alone," ERSP said June 24. The Council of Better Business Bureaus program made similar recommendations for nearly identical claims for Zylotrim, which contains 7-Keto DHEA, the same active ingredient as MytoSlim (1"The Tan Sheet" March 30, 2009, In Brief)

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts